Literature DB >> 28128076

Assessment of Cardiovascular Risk Factors in Patients with Psoriasis.

Olivia Komorowska, Michal Bohdan, Aneta Szczerkowska-Dobosz1, Dorota Rawicz-Zegrzda, Maria Dudziak, Tomasz Zdrojewski, Marcin Gruchala, Dorota Purzycka-Bohdan, Roman Nowicki.   

Abstract

Psoriasis is a chronic inflammatory skin disorder associated with increased cardiovascular risk. Aim of this work was to evaluate the association between psoriasis and chosen cardiovascular risk factors, echocardiographic parameters, and carotid intima-media thickness. A total of 50 patients with psoriasis and 50 controls were enrolled in the study. Psoriasis area severity index was calculated in the study group. Systolic and diastolic blood pressure, body mass index, waist circumference, lipids, fasting glucose, and D-dimer levels were assessed in all patients. In addition, echochardiographic parameters and carotid intima-media thickness were measured. Patients with psoriasis had higher blood pressure (P=0.001), elevated triglycerides (P=0.0218), lower high-density lipoprotein cholesterol (HDL-C) (P=0.0014), elevated D-dimer levels (p=0.0009), and were more frequently overweight (P=0.0198) in comparison to controls. There were no differences in echocardiographic parameters and carotid intima-media thickness between the psoriasis and control groups. Moreover, a positive correlation between psoriasis area severity index and blood pressure was observed (P=0.0088). The study confirmed that psoriasis is associated with increased cardiovascular risk. The association between psoriasis, intima-media thickness, and echocardiographic parameters should be evaluated in large prospective studies.

Entities:  

Mesh:

Year:  2016        PMID: 28128076

Source DB:  PubMed          Journal:  Acta Dermatovenerol Croat        ISSN: 1330-027X            Impact factor:   1.256


  1 in total

1.  Evaluation of plasma levels of tissue factor and tissue factor pathway inhibitor in patients with psoriasis.

Authors:  Anna Domagała; Elżbieta Wojtowicz-Prus; Joanna Dubis; Wojciech Witkiewicz; Anna Czarnecka
Journal:  Postepy Dermatol Alergol       Date:  2019-08-30       Impact factor: 1.837

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.